Berberine Administration in Treatment of Colitis: A Review.
Antioxidant
Berberis aquifolium
anti-inflammatory
berberine
colitis
inflammatory bowel disease
Journal
Current drug targets
ISSN: 1873-5592
Titre abrégé: Curr Drug Targets
Pays: United Arab Emirates
ID NLM: 100960531
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
02
2020
revised:
31
03
2020
accepted:
23
04
2020
pubmed:
23
6
2020
medline:
22
9
2021
entrez:
23
6
2020
Statut:
ppublish
Résumé
Berberine (Brb) is one of the well-known naturally occurring compounds exclusively found in Berberis vulgaris and other members of this family, such as Berberis aristata, Berberis aroatica, and Berberis aquifolium. This plant-derived natural compound has a variety of therapeutic impacts, including anti-oxidant, anti-inflammatory, anti-diabetic, and anti-tumor. Multiple studies have demonstrated that Brb has great anti-inflammatory activity and is capable of reducing the levels of proinflammatory cytokines, while it enhances the concentrations of anti-inflammatory cytokines, making it suitable for the treatment of inflammatory disorders. Colitis is an inflammatory bowel disease with chronic nature. Several factors are involved in the development of colitis and it appears that inflammation and oxidative stress are the most important ones. With respect to the anti-inflammatory and antioxidant effects of Brb, its administration seems to be beneficial in the treatment of colitis. In the present review, the protective effects of Brb in colitis treatment and its impact on molecular pathways are discussed.
Identifiants
pubmed: 32564751
pii: CDT-EPUB-107531
doi: 10.2174/1389450121666200621193758
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Antioxidants
0
Cytokines
0
Plant Extracts
0
Berberine
0I8Y3P32UF
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1385-1393Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.